Table 6 Third line therapies after failure of Docetaxel/Oxaliplatin treatment
Third line therapy (n = 15) | ||
|---|---|---|
Treatment | Number of Patients | Percent |
Gemcitabine + Capecitabine | 8 | 53.3 |
5-FU/Oxaliplatin based | 3 | 20 |
5-FU/Irinotecan based | 4 | 26.7 |
Third line therapy (n = 15) | ||
|---|---|---|
Treatment | Number of Patients | Percent |
Gemcitabine + Capecitabine | 8 | 53.3 |
5-FU/Oxaliplatin based | 3 | 20 |
5-FU/Irinotecan based | 4 | 26.7 |